The increasing need to improve the pharmacological response of drugs and to check their efficiency over time has propelled the need for transdermal and transmucosal drug delivery systems in clinical practices. Such delivery systems have been proved to be productive in terms of references for new chemical entities. Multiple companies in the pharmaceutical sector are focusing on improving the therapeutic outcomes of already approved drugs by the Food and Drug Administration of the United States, considering the time gap for approval and consistency of the drug content. Therefore, alternative delivery systems are used for achieving this objective so as to ensure growth in patient compliance.
With the recent pandemic facing the world, the global transdermal and transmucosal drug delivery systems market has gained immense traction owing to the need for alternative drug delivery systems. Some of the key vendors operating in this market include TEVA Pharmaceutical Industries Ltd., Aveva Drug Delivery Systems, ALZA Corporation, 3M, DURECT Corporation, Medipatch INC., and others.
Transdermal drug delivery systems (TDDS) started in 1979 where it was first used for nausea and vomiting. Also known commonly as patches, TDDS is a method that uses intact skin, as a means of administering drugs into the body’s circulatory system. A transdermal patch is applied on the skin and is considered a free dose form, wherein the skin helps to transport the content of the medication in an organized manner in the body of the receiver. Such delivery systems offer multiple benefits such as decreasing the need for multiple dosages, improving patient compliance, avoiding the first-pass effect, allowing the use of drugs with shorter shelf life, and evading chemically unfriendly gastrointestinal system environment. These systems also offer drug input and controlled release of potent drugs and are easily removable in case of a reaction. Such salient features are likely to bode well for the growth of the global transdermal drug delivery systems market.